Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Insights from 2023 WCLC
B

WCLC 2023 Insights: "3-Year Outcomes & Correlative Analyses in Patients With NSCLC and a Very High PD-L1 Tumor Proportion Score ≥ 90% Treated With 1L Cemiplimab & Pembro"

By Insights from 2023 WCLC FEATURING Biagio Ricciuti
By Insights from 2023 WCLC FEATURING Biagio Ricciuti
82 views
October 9, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Lung
29:32
Dana-Farber Cancer Institute

Updates in KRAS G12C Mutant NSCLC: Demographics, Clinical Features, …

Feat. B. Ricciuti
02:35
ecancer

ESMO 2023 Insights: "Phase 2 KRYSTAL-7 Trial - Adagrasib+Pembro…

Feat. P. Janne
05:48
Insights from 2023 WCLC

WCLC 2023 Insights: "Association of TTF-1 Expression With Outco…

Feat. A. Di Federico
09:08
Insights from 2023 WCLC

WCLC 2023 Insights: "Mechanisms of Resistance to KRAS G12C Inhi…

Feat. B. Ricciuti
09:57
Insights from 2023 WCLC

WCLC 2023 Insights: "3-Year Outcomes & Correlative Analyses…

Feat. B. Ricciuti
15:30
Dana-Farber Cancer Institute

Small Cell Lung Cancer: A Brief Review of the Treatment Landscape

Feat. J. Sands